(19)
(11) EP 3 503 877 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
20.04.2022 Bulletin 2022/16

(45) Mention of the grant of the patent:
16.03.2022 Bulletin 2022/11

(21) Application number: 17761698.4

(22) Date of filing: 23.08.2017
(51) International Patent Classification (IPC): 
A61K 9/14(2006.01)
A61K 9/16(2006.01)
A61K 47/34(2017.01)
A61K 9/113(2006.01)
A61K 38/48(2006.01)
A61K 9/00(2006.01)
A61K 47/36(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 9/0024; A61K 47/34; A61K 47/36; A61K 9/113; A61K 9/143; A61K 9/146; A61K 9/1647; A61K 9/0019; A61K 38/4893
(86) International application number:
PCT/US2017/048174
(87) International publication number:
WO 2018/039318 (01.03.2018 Gazette 2018/09)

(54)

BIODEGRADABLE POLYMER FORMULATIONS FOR EXTENDED EFFICACY OF BOTULINUM TOXIN

BIOLOGISCH ABBAUBARE POLYMERFORMULIERUNGEN FÜR VERLÄNGERTE WIRKUNG VON BOTULINUMTOXIN

FORMULATIONS DE POLYMÈRE BIODÉGRADABLE POUR PROLONGER L'EFFICACITÉ DE LA TOXINE BOTULIQUE.


(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 26.08.2016 US 201662380229 P

(43) Date of publication of application:
03.07.2019 Bulletin 2019/27

(73) Proprietor: SK Joint Ventures II, LLC
New York, New York 10128 (US)

(72) Inventors:
  • PARK, Kinam
    West Lafayette IN 47906 (US)
  • YUN, Yeonhee
    Whitestown Indiana 46075 (US)
  • SKIDMORE, Sarah Michelle
    Lafayette IN 47909 (US)
  • LEE, Byung Kook
    Whitestown Indiana 46075 (US)
  • GARNER, John Solomon
    West Lafayette IN 47906 (US)

(74) Representative: Potter Clarkson 
The Belgrave Centre Talbot Street
Nottingham NG1 5GG
Nottingham NG1 5GG (GB)


(56) References cited: : 
US-A1- 2010 310 669
US-B1- 6 312 708
US-A1- 2016 175 410
   
  • JIANJUN WANG ET AL: "Stabilization and encapsulation of human immunoglobulin G into biodegradable microspheres", JOURNAL OF COLLOID AND INTERFACE SCIENCE, vol. 271, no. 1, March 2004 (2004-03), pages 92-101, XP055092590, ISSN: 0021-9797, DOI: 10.1016/j.jcis.2003.08.072
  • LU YING ET AL: "Microparticles produced by the hydrogel template method for sustained drug delivery", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER, AMSTERDAM, NL, vol. 461, no. 1, 11 December 2013 (2013-12-11), pages 258-269, XP028810400, ISSN: 0378-5173, DOI: 10.1016/J.IJPHARM.2013.11.058 cited in the application
  • YE M ET AL: "Issues in long-term protein delivery using biodegradable microparticles", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 146, no. 2, September 2010 (2010-09), pages 241-260, XP027194174, ISSN: 0168-3659 [retrieved on 2010-05-19] cited in the application
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).